Donepezil hydrochloride
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Alzheimer's Disease
Conditions
Alzheimer's Disease, Dementia
Trial Timeline
Jan 1, 2001 → Sep 1, 2005
NCT ID
NCT00096473About Donepezil hydrochloride
Donepezil hydrochloride is a phase 3 stage product being developed by Eisai for Alzheimer's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00096473. Target conditions include Alzheimer's Disease, Dementia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02448784 | Pre-clinical | Completed |
| NCT02162264 | Pre-clinical | Completed |
| NCT02162251 | Pre-clinical | Completed |
| NCT01251718 | Pre-clinical | Completed |
| NCT01129596 | Pre-clinical | Completed |
| NCT00477659 | Approved | Completed |
| NCT00165750 | Approved | Terminated |
| NCT00165724 | Approved | Completed |
| NCT00165737 | Phase 3 | Completed |
| NCT00165659 | Phase 2 | Completed |
| NCT00096473 | Phase 3 | Completed |
Competing Products
20 competing products in Alzheimer's Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY450139 + Placebo | Eli Lilly | Phase 3 | 77 |
| Solanezumab + Placebo | Eli Lilly | Phase 3 | 77 |
| LY450139 dihydrate + placebo | Eli Lilly | Phase 2 | 52 |
| GSK4527226 | Alector | Phase 2 | 44 |
| GSK4527226 | Alector | Phase 2 | 44 |
| AL002 | Alector | Phase 2 | 44 |
| Solanezumab + Placebo | Eli Lilly | Phase 3 | 77 |
| simufilam | Cassava Sciences | Phase 2 | 44 |
| Remternetug + Placebo | Eli Lilly | Phase 3 | 77 |
| solanezumab | Eli Lilly | Phase 2 | 52 |
| LY2886721 + Placebo | Eli Lilly | Phase 1 | 33 |
| Gantenerumab + Gantenerumab + Gantenerumab + Placebo | Chugai Pharmaceutical | Phase 1 | 33 |
| Alfoatirin® Tab. + Aripezil® Tab. + Aripezil® Tab. | Yuhan | Approved | 85 |
| FK962 | Astellas Pharma | Phase 2 | 52 |
| ASP0777 + Placebo | Astellas Pharma | Phase 1 | 33 |
| Elenbecestat + Placebo | Eisai | Phase 3 | 77 |
| Donepezil | Eisai | Approved | 85 |
| Aricept (donepezil SR 23 mg) + Aricept (donepezil IR 10 mg) | Eisai | Phase 3 | 77 |
| Donepezil Hydrochloride | Eisai | Pre-clinical | 23 |
| Lecanemab IV + Placebo + Lecanemab SC | Eisai | Phase 3 | 77 |